Does breast cancer tumor size really matter that much?

Breast

Volumn 21, Issue 5, 2012, Pages 682-685

  Provencher, Louise ^a,b   Diorio, Caroline ^a,b   Hogue, Jean Charles ^a   Doyle, Catherine ^a,b   Jacob, Simon ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Breast cancer; Cancer treatment; Genomic signature; Tumor size

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL DECISION MAKING; HUMAN; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR VOLUME;

EID: 84865988469     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.07.003     Document Type: Article

References (32)

1. Fisher E.R., Sass R., Fisher B. Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4). X. discriminants for tenth year treatment failure. Cancer 1984, 53:712-723.
2. Veronesi U., Cascinelli N., Greco M., Bufalino R., Morabito A., Galluzzo D., et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985, 202:702-707.
3. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
4. Tinnemans J.G., Wobbes T., Holland R., Hendriks J.H., Van der Sluis R.F., De Boer H.H. Treatment and survival of female patients with nonpalpable breast carcinoma. Ann Surg 1989, 209:249-253.
5. Leitner S.P., Swern A.S., Weinberger D., Duncan L.J., Hutter R.V. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, b N0 M0). Cancer 1995, 76:2266-2274.
6. Sloane J.P., Ellman R., Anderson T.J., Brown C.L., Coyne J., Dallimore N.S., et al. Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U.K. National Coordinating Group for breast screening pathology. Eur J Cancer 1994, 30A:1414-1419.
7. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
8. Cady B. Use of primary breast carcinoma characteristics to predict lymph node metastases. Cancer 1997, 79:1856-1861. discussion 1862-1854.
9. Seidman J.D., Schnaper L.A., Aisner S.C. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 1995, 75:65-71.
10. American Joint Committee on Cancer (AJCC) cancer staging manual 2010, Springer, New York. 7th ed.
11. TNM classification of malignant tumours 2010, Wiley, Hoboken. 7th ed.
12. Hammond M.E., Fitzgibbons P.L., Compton C.C., Grignon D.J., Page D.L., Fielding L.P., et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med 2000, 124:958-965.
13. Lester S.C., Bose S., Chen Y.Y., Connolly J.L., de Baca M.E., Fitzgibbons P.L., et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast 2009, College of American Pathologists (CAP), Version 3.0.0.0.
14. Pritt B., Ashikaga T., Oppenheimer R.G., Weaver D.L. Influence of breast cancer histology on the relationship between ultrasound and pathology tumor size measurements. Mod Pathol 2004, 17:905-910.
15. Apple S.K., Suthar F. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?. Breast 2006, 15:370-376.
16. Behjatnia B., Sim J., Bassett L.W., Moatamed N.A., Apple S.K. Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. Int J Clin Exp Pathol 2010, 3:303-309.
17. Pritt B., Tessitore J.J., Weaver D.L., Blaszyk H. The effect of tissue fixation and processing on breast cancer size. Hum Pathol 2005, 36:756-760.
18. Michaelson J.S., Satija S., Kopans D., Moore R., Silverstein M., Comegno A., et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer 2003, 98:2114-2124.
19. Carlson R.W., Allred D.C., Anderson B.O., Burstein H.J., Carter W.B., Edge S.B., et al. NCCN clinical practice guidelines in oncology: breast cancer 2010, V.1.2010 edn, National Comprehensive Cancer Network (NCCN), Fort Washington.
20. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
21. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
22. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
23. Chang J., Powles T.J., Allred D.C., Ashley S.E., Clark G.M., Makris A., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999, 17:3058-3063.
24. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369.
25. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Tham Y.L., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005, 23:1169-1177.
26. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284-2293.
27. Wo J.Y., Chen K., Neville B.A., Lin N.U., Punglia R.S. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 2011, 29:2619-2627.
28. Ugnat A.M., Xie L., Morriss J., Semenciw R., Mao Y. Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 2004, 90:1138-1143.
29. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
30. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948.
31. Norton L., Massague J. Is cancer a disease of self-seeding?. Nat Med 2006, 12:875-878.
32. Comen E.A., Norton L., Massague J. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. J Clin Oncol 2011, 29:2610-2612.